2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
06/26/17Ocular Therapeutix™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
06/22/17Ocular Therapeutix™ Announces Executive Transition PlansPrinter Friendly Version
06/01/17Ocular Therapeutix™ to Present at Two Upcoming Investor ConferencesPrinter Friendly Version
05/11/17Ocular Therapeutix™ Presented Phase 3 Data for DEXTENZA™ at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingPrinter Friendly Version
05/09/17Ocular Therapeutix™ Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of Sustained Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX-TKI) at the ARVO Annual MeetingPrinter Friendly Version
05/08/17Ocular Therapeutix™ Presents Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) SymposiumPrinter Friendly Version
05/05/17Ocular Therapeutix™ Reports First Quarter 2017 Financial ResultsPrinter Friendly Version
05/02/17Ocular Therapeutix™ to Present Data on Anterior and Posterior Segment Drug Product Candidates at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingPrinter Friendly Version
05/01/17Ocular Therapeutix™ to Report First Quarter 2017 Financial ResultsPrinter Friendly Version
04/24/17Ocular Therapeutix™ to Present Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) SymposiumPrinter Friendly Version
04/06/17Ocular Therapeutix™ Appoints George Migausky as Interim Chief Financial OfficerPrinter Friendly Version
03/15/17New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix’ DEXTENZA™ Following Cataract SurgeryPrinter Friendly Version
03/10/17Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2016 Financial ResultsPrinter Friendly Version
03/08/17Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2016 Financial ResultsPrinter Friendly Version
02/22/17Ocular Therapeutix™ Announces FDA Acceptance of NDA Resubmission for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic SurgeryPrinter Friendly Version
02/09/17Ocular Therapeutix™ to Present at Three Upcoming Investor ConferencesPrinter Friendly Version
01/24/17Ocular Therapeutix, Inc. Announces Pricing of Public Offering of Common StockPrinter Friendly Version
01/23/17Ocular Therapeutix, Inc. Announces Public Offering of Common StockPrinter Friendly Version
01/23/17Ocular Therapeutix™ Resubmits NDA for DEXTENZA™ for the Treatment of Ocular Pain Occurring After Ophthalmic SurgeryPrinter Friendly Version
01/04/17Ocular Therapeutix™ Announces Additional Successful Results for Phase 3 Clinical Trial of DEXTENZA™Printer Friendly Version